ClinicalTrials.gg
RecruitingNCT07435987ARCHITECTUpdated Sep 25, 2026

Clinical Feasibility of the ARCHITECT Applicator in Cervical Cancer Brachytherapy

An interventional study of ARCHITECT applicator in Locally Advanced Cervical Cancer and Uterine Carcinoma, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Sep 25, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Uterine Cervical Neoplasms with a site in Netherlands — 15 open to participants now, 18 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Netherlands.

Planned enrollment
33rd of 41
25 · median 214
Started
2026
with 3 others
No phase
9 of 53
3 open now
Primary completion
2027-12
later than 6 of 17 live
Registered
51st of 53
by date

Among the 53 studies in Uterine Cervical Neoplasms with a site in Netherlands, this one is the 33rd largest by planned enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2026, is one of 9 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 51st registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

15 of the 53 studies in Uterine Cervical Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Uterine Cervical Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

This prospective, non-randomised, single centre, phase I trial assesses the clinical feasibility of the use of the patient-tailored ARCHITECT applicator in locally advanced cervical cancer brachytherapy.

Read the detailed description

Image-guided adaptive brachytherapy is an essential part of the standard treatment of locally advanced cervical cancer (LACC). During LACC brachytherapy, a radioactive source is guided through an applicator implanted in the vaginal and uterine cavity, as well as through interstitial needles near or inside the tumour tissue. However, in certain patient groups, current commercially available applicators cannot meet dose objectives. Alternative approaches are technically challenging and dependent on the clinician's experience.

In the ARCHITECT project, a single-use, 3D printed, patient-tailored applicator with optimised source channels is developed to overcome these limitations. The aim of this phase I study is to evaluate the clinical feasibility of the ARCHTECT applicator in brachytherapy for LACC.

Twenty-five patients with LACC will be treated with the standard treatment for LACC in concordance with the EMBRACE II protocol and (inter)national guidelines, including external beam radiation therapy (45 Gy in 25 fx with simultaneous integrated nodal boost in case of suspicion of lymph node metastases), concurrent weekly chemotherapy (cisplatin 40 mg/m2), and high-dose rate (HDR) image-guided adaptive brachytherapy (IGABT). HDR IGABT will be performed following the latest clinical guidelines, including 21-28 Gy in 3 to 4 fractions of 7 Gy, aiming for a total cumulative (EBRT+IGABT) dose of 90-95 Gy (EQD210 D90) to the high-risk-clinical target volume (CTV-THR). Deep hyperthermia in five sessions or no sensitizing therapy during EBRT is also allowed.

In general in Erasmus Medical Centre, two applications are applied with an interval of one week for the brachytherapy part. Patients will be treated with a commercially available applicator (conform the current clinical practice) at week 1 and with the patient-tailored ARCHITECT applicator (study intervention) at week 2.

03

Conditions studied

  • Locally Advanced Cervical Cancer
  • Uterine Carcinoma

Keywords

  • Brachytherapy
  • Patient-tailored applicator
  • 3D-printed applicator
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced cervical cancer (FIGO 2018 stage 1B3-IVA) with indication for primary radiotherapy including brachytherapy
  • Written

Exclusion criteria

Exclusion Criteria:

  • Unable to give ;
  • Tumour extension in the lower 2/3rd of the vagina;
  • Requiring a Geneva tandem with ovoids' size 13 mm in the first application for brachytherapy;
  • Known nylon allergy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Study arm

    In general in Erasmus Medical Centre, two applications are applied with an interval of one week for the HDR IGABT. Patients will be treated with a commercially available applicator (conform the current clinical practice) at week 1 and with the patient-tailored ARCHITECT applicator (study intervention) at week 2.

    Device: ARCHITECT applicator

Interventions

  • DeviceARCHITECT applicator

    Patient-tailored, 3D-printed applicator

06

What researchers measure

Primary outcomes

  1. Clinical feasibility

    To deliver brachytherapy using the patient-tailored, 3D printed ARCHITECT applicator \[yes/no\]

    Time frame: At week 2 (ARCHITECT applicator)

Secondary outcomes

  1. Brachytherapy-related adverse events

    Organ perforation, vaginal bleeding, and device-related infection according to the common terminology criteria for adverse events (CTCAE) version 5

    Time frame: At week 1 (standard applicator) and week 2 (ARCHITECT applicator): based on imaging (organ perforation), <1 hour after applicator removal (vaginal bleeding), <1-2 weeks after removal from the patient (device-related infection)

  2. Brachytherapy plan quality

    Dosimetric parameters (according to EMBRACE II): High-Risk Clinical Target Volume D90, High-Risk Clinical Target Volume D98, Intermediate-Risk Clinical Target Volume D98, and bladder , rectum , sigmoid , and bowel D2cm3 \[Gy\]

    Time frame: At week 1 (standard applicator) and week 2 (ARCHITECT applicator)

  3. Brachytherapy implant geometry

    Optimal geometry of applicator, i.e. number of needles and spacing between needles \[mm\]

    Time frame: At week 1 (standard applicator) and week 2 (ARCHITECT applicator)

  4. User experience

    Questions on a scale of 1-5 where 1 indicates "strongly disagree" and 5 "strongly agree" on following the topics: easy to insert applicator, easy to connect applicator to tandem, easy to insert the needles in terms of force, easy to reach required depth with needles, easy to fixate the needles, applicator fits well, easy to remove applicator and needles, easy to reconstruct applicator or needles, applicator did not move, needles did not move, easy to connect and disconnect to after loader.

    Time frame: At week 1 (standard applicator) and 2 (ARCHITECT applicator)

  5. Time required for the workflow

    Process steps evaluated on time: designing the applicator, processing at manufacturer, processing before use, in operating room, delineating targets and organs-at-risk, reconstructing, treatment planning, checking, treating, removing applicator \[hours:minutes\]

    Time frame: At week 1 (standard applicator) and week 2 (ARCHITECT applicator)

  6. Pain perceived by patient

    Perceptions of pain will be assessed using the 11-point, Numeric Rating Scale (NRS-11), where 0 indicates "no pain" and 10 represents the "worst imaginable pain"

    Time frame: At week 1 (standard applicator) and week 2 (ARCHITECT applicator): <1 hour before the patient arrives at operating room, after each MR or CT imaging, and after removal from the patient

  7. Integrity of the patient-tailored applicator

    The ARCHITECT applicator will be visually inspected to detect any signs of compromised integrity: breakage \[yes/no\], cracking \[yes/no\], deformation \[yes/no\], material loss \[yes/no\].

    Time frame: At week 2 (ARCHITECT applicator): after removal from the patient

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Straathof R, van Vliet-Perez SM, Kolkman-Deurloo IK, Wauben LSGL, Nout RA, Heijmen BJM, Rossi L, Dankelman J, van de Berg NJ. Automated planning of curved needle channels in 3D printed patient-tailored applicators for cervical cancer brachytherapy. Phys Med Biol. 2024 Nov 25;69(23). doi: 10.1088/1361-6560/ad8b08. PubMed 39447602 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 17 months is below that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jul 2026, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 27, 2026
StartActual
Jul 22, 2026was May 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 25, 2026
Sites
Erasmus Medical Center is now Recruiting
Sep 25, 2026
Start date
May 2026→Jul 22, 2026 (actual)
Sep 25, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Erasmus Medical Center · Rotterdam, NetherlandsContact person changed (no phone or email listed)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Not yet recruiting→Recruiting
    Erasmus Medical Center is now Recruiting
    Start date May 2026→Jul 22, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Erasmus Medical Center · Rotterdam, NetherlandsContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07435987
Responsible party
Dr. G.H. (Henrike) Westerveld (Radiation oncologist, Erasmus Medical Center) — Principal investigator
First posted
Feb 27, 2026
Start date
Jul 22, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

H. Westerveld, MD, PhD
Contact
g.westerveld@erasmusmc.nl
+31 10 704 1249

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion